ORAMED PHARMACEUTICALS INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.0M | — | $1.3M | $2.7M | — |
| Cost of revenue | $2.0M | — | — | — | — |
| Gross profit | $13,000 | — | — | — | — |
| Research and development | $6.4M | $6.3M | $9.0M | $27.6M | — |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | — |
| Interest expense | — | $853,000 | $2.0M | — | — |
| Pretax income | $75.3M | -$15.9M | $5.1M | -$37.7M | — |
| Income tax expense | $11.3M | $3.2M | — | $100,000 | — |
| Net income | $64.0M | -$19.1M | $5.1M | -$36.6M | — |
| Balance Sheet | |||||
| Cash and equivalents | $45.9M | $54.4M | $9.1M | $40.5M | — |
| Current assets | $133.3M | $143.2M | $162.6M | $157.1M | $147.9M |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $177.8M |
| Current liabilities | $19.1M | $5.7M | $53.2M | $5.7M | $7.4M |
| Stockholders' equity | $199.7M | $146.3M | $163.8M | $151.8M | $166.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.1M | -$8.4M | -$10.3M | -$27.9M | — |
| Depreciation and amortization | $121,000 | $193,000 | $196,000 | $58,000 | — |
| Stock-based compensation | $6.0M | $4.1M | $4.2M | $11.5M | — |
| Capital expenditure | $9,000 | $18,000 | $254,000 | $496,000 | — |
| Free cash flow | -$9.2M | -$8.4M | -$10.5M | -$28.4M | — |
| Share repurchases | $4.7M | $2.5M | — | — | — |
Shares outstanding 40.9M · Free float 32.1%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.